Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 27Recruiting 20Unknown 18Terminated 7Not yet recruiting 7Active not recruiting 6Withdrawn 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1

Conditions

Hematologic Neoplasms 1Barrett Esophagus 1

Interventions

Cyclophosphamide 129Cisplatin 119Radiotherapy 115pembrolizumab 111Carboplatin 97Paclitaxel 96Gemcitabine 96Magnetic Resonance Spectroscopy 80Nivolumab 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Biopsy 53Doxorubicin 52fludarabine 51Drug Therapy 45durvalumab 44Cytarabine 44Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Surveys and Questionnaires 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Endoscopy × Clear all
NCT05660421 2026-04-27

Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors

Vanderbilt-Ingram Cancer Center

Phase 2 Withdrawn
Other hematologic neoplasm

Hematologic Neoplasms

NCT01209013 2012-05-08

Oedisse

Pinnacle Biologics Inc.

Phase 3 Withdrawn
Gastrointestinal

Barrett Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡